ЛИТЕРАТУРА

Поставить закладку

International Committee on Taxonomy of Viruses. Available online: https://ictv.global/taxonomy. Accessed on July 10, 2023.
Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science. 2009;326(5957):1279–1283. doi: https://doi. org/10.1126/science.1177634
Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Glob Health. 2015;5(1):010408. doi: https://doi.org/10.7189/ jogh.05.010408
Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510–517. doi: https://doi.org/10.1097/ INF.0b013e3182184ae7
Jansen R, Bont L, Siezen CLE, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis. 2007;196(6):825–834. doi: https://doi.org/10.1086/520886
Вишнева Е.А., Намазова-Баранова Л.С., Торшхоева Р.М. и др. Паливизумаб: новые возможности в профилактике астмы? // Педиатрическая фармакология. — 2011. — Т. 8. — № 3. — С. 24–30.
Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health. 2019;7(8): e1031–e1045. doi: https://doi.org/10.1016/S2214-109X(19)30264-5
Ровный В.Б. Лобзин Ю.В., Бабаченко И.В. и др. Клинико-эпидемиологические особенности респираторно-синцитиальной инфекции у детей разного возраста // Журнал инфектологии. — 2014. — Т. 5. — № 2. — С. 76–81. — doi: https://doi.org/10.22625/2072-6732-2013-5-2-76-81
Бабаченко И.В., Самодова О. В., Анохин В. А. и др. Клинико-эпидемиологические особенности респираторно-синцитиальной вирусной инфекции у детей первого года жизни // Журнал инфектологии. — 2018. — Т. 10. — № 3. — С. 70–76. — doi: https://doi.org/10.22625/2072-6732-2018-10-3-70-76
Давыдова И.В., Овсянников Д. Ю., Кршеминская И. В., Рудакова А. В. Новые подходы к иммунопрофилактике тяжелого течения респираторно-синцитиальной вирусной инфекции у детей // Педиатрия. Журнал им. Г.Н. Сперанского. — 2019. — Т. 98. — № 5. — С. 110–113.
Abu-Raya B, Reicherz F, Lavoie PM. Correlates of protection against respiratory syncytial virus infection in infancy. Clin Rev Allergy Immunol. 2022;63(3):371–380. doi: https://doi.org/10.1007/s12016-022-08948-8
Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis. 2014;209(11):1685–1692. doi: https://doi.org/10.1093/infdis/jit828
Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and metaanalysis. Influenza Other Respir Viruses. 2023;17(1): e13031. doi: https://doi.org/10.1111/irv.13031
Abu Raya B, Paramo M, Reicherz F, Lavoie P. Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine. 2023;61:102089. doi: https://doi.org/10.1016/j.eclinm.2023.102089
Ting S, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi: https://doi.org/10.1016/S0140-6736(17)30938-8
Pınarbaşı Ş, Koçak C. Tripledemic: COVID-19, İnfluenza ve RSV. In: 11th International Hippocrates Congress on Medical and Health Sciences. 2023. Р. 269.
Киселева И.В., Ксенафонтов А. Д. Ринои РС-вирусы в пандемию COVID-19 // Инфекция и иммунитет. — 2022. — Т. 12. — № 4. — C. 624– 638. — doi: https://doi.org/10.15789/2220-7619-RAR-1826
Бабаченко И.В., Орлова Е.Д., Лобзин Ю.В. Влияние пандемии COVID-19 на сезонность респираторно-синцитиальной вирусной инфекции // Журнал инфектологии. — 2022. — Т. 14. — № 2. — С. 39–46. — doi: https://doi.org/10.22625/2072-6732-2022-14-2-39-46
Burki TK. Circulation of influenza, RSV, and SARS-CoV-2: an uncertain season ahead. Lancet Respir Med. 2021;9(10): e103. doi: https://doi.org/10.1016/S2213-2600(21)00364-7
Bozzola E, Sarah B, Villani A. Respiratory syncytial virus pediatric hospitalization in the COVID-19 era. Int J Environ Res Public Health. 2022;19(23):15455. doi: https://doi.org/10.3390/ijerph192315455
Fourgeaud J, Toubiana J, Chappuy H, et al. Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. Eur J Clin Microbiol Infect Dis. 2021;40(11):2389–2395. doi: https://doi.org/10.1007/s10096-021-04323-1
Sah R, Zaman K, Mohanty A, et al. Respiratory syncytial virus with ongoing COVID-19: is it an emerging threat? Ann Med Surg (Lond). 2023;85(1):67–70. doi: https:// doi.org/10.1097/MS9.0000000000000153
Ali S, Plint AC, Klassen TP. Bronchiolitis. In: Kendig & Chernick’s Disorders of the Respiratory Tract in Children. 2012. pp. 443–52.
Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2011;5:144–154. doi: https://doi.org/10.2174/1874285801105010144
Binns E, Tuckerman J, Licciardi PV, Wurzel D. Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions. J Paediatr Child Health. 2022;58(10):1741–1746. doi: https://doi.org/10.1111/ jpc.16197
Kabego L, de Beer C. Association between Respiratory Syncytial Virus Infection in Infancy and Subsequent Asthma: A Meta-Analysis of Observational Studies. JSM Allergy Asthma. 2017;2(1):1009.
Shi T, Ooi Y, Zaw EM, et al. Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood. J Infect Dis. 2020;222(Suppl 7):S628–S633. doi: https://doi. org/10.1093/infdis/jiz311
Jung JW. Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV–CHD survey. Korean J Pediatr. 2011;54(5):192–196. doi: https://doi.org/10.3345/kjp.2011.54.5.192
Reeves RM, van Wijhe M, Lehtonen T, Stona L, et al. A systematic review of European clinical practice guidelines for respiratory syncytial virus prophylaxis. J Infect Dis. 2022;226(1):S110–S116. doi: https://doi. org/10.1093/infdis/jiac059
Постановление Главного государственного санитарного врача Российской Федерации от 28 января 2021 г. № 4 «Об утверждении санитарных правил и норм СанПиН 3.3686-21 «Санитарноэпидемиологические требования по профилактике инфекционных болезней».
Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519–530. doi: https://doi.org/10.1542/pir.35-12-519
Luna MS, Manzoni P, Paes B, et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020;33:35– 44. doi: https://doi.org/10.1016/j.prrv.2018.12.001
Manti S, Staiano A, Orfeo L, et al. UPDATE-2022 Italian guidelines on the management of bronchiolitis in infants. Ital J Pediatr. 2023;49(1):19. doi: https://doi.org/10.1186/s13052-022-01392-6
Resch B, Eber E, Ehringer-Schetitska D, et al. Respiratory Syncytial Virus Prophylaxe mit Palivizumab 2019. Update der Empfehlungen der Österreichischen Gesellschaft für kinder-und Jugendheilkunde. Padiatr Padol. 2019;54:270–276. doi: https://doi.org/10.1007/s00608-019-00725-9
Баранов А.А., Иванов Д.О., Алямовская Г.А. и др. Паливизумаб: четыре сезона в России // Вестник Российской академии медицинских наук. — 2014. — № 7–8. — С. 54–68.
Инструкция по медицинскому применению лекарственного препарата Синагис® 100 мг (раствор для внутримышечного введения) с учетом изменений № 1, 2. Регистрационное удостоверение № ЛП-005242 от 10.12.2018 (переоформлено 24.01.2023).
Stewart DL, Ryan KJ, Seare JG, et al. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. BMC Infect Dis. 2013;13:34. doi: https://doi.org/10.1186/1471-2334-13-334
Palivizumab passive immunization against Respiratory Syncytial Virus (RSV) in at risk pre-term infants. Available online: https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2021/07/phe-ref-ra-21.035-palivizumab-passive-immunisation-against-respiratory-syncytial-virus-rsv-in-at-risk-pre-term.pdf. Accessed on March 25, 2023.
Palivizumab passive immunization against respiratory syncytial virus (RSV) in at risk pre-term infants. In: RCPCH: Royal College of Paediatrics and Child Health: Official website. Available online: https://www. rcpch.ac.uk/news-events/news/palivizumab-passive-immunisation-against-rsv-pre-term-infants. Accessed on March 25, 2023.
Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022–2023 RSV. In: American Academy of Pediatrics: Official website. Available online: https://www.aap.org/en/pages/20 19-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization. Accessed on March 03, 2023.
Информационное письмо: О рекомендуемых сроках проведения иммунопрофилактики респираторно-синцитиальной вирусной инфекции у детей из групп риска // ФГБУ ДНКЦИБ ФМБА России: официальный сайт. Доступно по: http://niidi.ru/news/informatsionnoe-pis-mo-o-rekomenduemykh-srokakh-provedeniya-immunoprofilaktiki-respiratorno-sintsitial-noy-virusnoy-infe. Ссылка активна на 13.03.2023.
Al-Alaiyan S, Pollack P, Notario GF. Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs Context. 2015;4:212270. doi: https://doi.org/10.7573/dic.212270
Миронова А.К. Опыт проведения пассивной иммунизации против респираторно-синцитиальной вирусной инфекции — двенадцатый сезон // РМЖ. Медицинское обозрение. — 2022. — Т. 6. — № 11. — С. 659–666 — doi: https://doi.org/10.32364/2587-6821-2022-6-11-659-666
Manuel O, Estabrook M. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9): e13511. doi: https://doi.org/10.1111/ctr.13511
Kroger A, Bahta L, Long S, Sanchez P. General Best Practice Guidelines for Immunization. Available online: https://www .cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed on July 10, 2023.
Public Health England. Green Book. Chapter 6: Contraindications and Special Considerations. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_ data/file/655225/Greenbook_chapter_6.pdf. Accessed on July 10, 2023.
Immunization NACo. Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab). Available online: http://publications.gc.ca/collections/Collection/H12-21-2-29-7.pdf. Accessed on July 10, 2023.
The Association of the Scientific Medical Societies in Germany (AWMF). Guideline for the Prophylaxis of Serious Diseases Caused by Respiratory Syncytial Virus (RSV) in Children at Risk: Update 2017/2018. Available online: https://www.awmf.org/uploads/tx_szleitlinien/0 48-012l_S2k_Prophylaxe-von-schweren_RSV-Erkrankungen-Risikokindern-Palivizumab_2018-11.pdf. Accessed on July 10, 2023.
RCH. Palivizumab for at-risk patients: Clinical guidelines. In: The Royal Children’s Hospital Melbourne: Official website. Available online: https://www.rch. org.au/rchcpg/hospital_clinical_guideline_index/ Palivizumab_for_at-risk_patients/#Documentation. Accessed on July 10, 2023.
American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014;134(2):e620–e638. doi: https://doi.org/10.1542/ peds.2014-1666
Beyfortus approved in the EU for the prevention of RSV lower respiratory tract disease in infants. In: European Medical Agency: Official website. Available online: https://www .ema.europa.eu/en/medicines/human/EPAR/beyfortus. Accessed on July 10, 2023.
Advisory Committee for the prevention of RSV lower respiratory tract disease in infants. In: AJMC: American Journal of Managed Care. Available online: https://www .ajmc.com/view/fda-advisory-committee-recommends-nirsevimab-vaccination-for-rsv-in-infants. Accessed on July 10, 2023.
Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–1477. doi: https://doi.org/10.1056/NEJMoa2213836
Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: June 21–23, 2023 Meeting. In: CDC: Centers for Disease Control and Prevention. Available online: https://www .cdc.gov/vaccines/acip/meetings/slides-2023-06-21-23.html. Accessed on July 10, 2023.